

External Evaluation of ACT-A: Overview of updates made to October 10 version

Section	Changes
Executive Summary	<ul style="list-style-type: none"> -Key finding 10: Provided additional details on role of agencies and FC RM working group in resource mobilization -Key finding 14: Changed from 'clearance' to 'guidance' -Key finding 15: Provided additional details on CoVDP's approach and mandate -Lessons learnt: Emphasized need to also invest in manufacturing capacity for diagnostics
Section 2	-Changed from 'Global Fund and UNITAID' to 'Diagnostics and Therapeutics pillars'
Section 3	-Added paragraph on role of agencies and FC RM working group in resource mobilization
Section 4	<ul style="list-style-type: none"> -Section 4.1: Additions on upstream contributions (e.g., call for \$2bn; contributions to Novavax manufacturing network; mRNA hubs). Edited section CoVDP. -Section 4.2: Small additions on Tx pillar, both upstream (...) and downstream (e.g., recommendations for outpatient treatments came in 2022 only). Additions on sources of funding for oxygen. -Section 4.3: Updated evidence on test evaluated and funding for manufacturing; highlighted how lack of immediate funds constrained procurement of tests -Section 4.5: Additions on data/method on use of funding
Section 5	<ul style="list-style-type: none"> -Need for Dx manufacturing capacity highlighted -Highlighted negative impact of trade barriers on production
Section 6	-Highlighted need for investing in Dx manufacturing to lessons learnt